Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer

BACKGROUND: The prognostic value and the best method of testing of topoisomerase II alpha (TOP2A) status have not been established in modern tailored therapy based on breast cancer subtype. RESULTS: The frequencies of TOP2A overexpression and TOP2A amplified were 55.8% and 9.5%, respectively. TOP2A...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigematsu, Hideo, Ozaki, Shinji, Yasui, Daisuke, Yamamoto, Hideki, Zaitsu, Junichi, Taniyama, Daiki, Saitou, Akihisa, Kuraoka, Kazuya, Hirata, Taizo, Taniyama, Kiyomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003555/
https://www.ncbi.nlm.nih.gov/pubmed/29928479
http://dx.doi.org/10.18632/oncotarget.25468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003555/
https://www.ncbi.nlm.nih.gov/pubmed/29928479
http://dx.doi.org/10.18632/oncotarget.25468

Ejemplares similares